Slide 1: Felix: From Clinical Validation to Global Commercial Scale
ASX: MEM | INVESTOR PRESENTATION · SEPTEMBER 2026 Felix : From Clinical Validation to Global Commercial Scale Regulatory approvals secured. Major commercial partners activated. Recurring cartridge revenue beginning to scale. MEMPHASYS · ASX: MEM 1
Slide 2: Commercial momentum is accelerating
COMMERCIAL INFLECTION POINT Commercial momentum is accelerating Felix is converting global market access into contracted demand A$4.2M+ 31+ 1,800 22 Minimum contracted sales Countries covered by agreements Cartridges ordered through Monash IVF clinics in potential publicly announced and commercial a
Slide 3: Each active clinic can generate recurring cartridge demand
PRODUCT & MARKET OPPORTUNITY Each active clinic can generate recurring cartridge demand A LARGE GLOBAL PROCEDURE BASE Breakthrough - Automates sperm selection in approximately six minutes Felix combines electrophoresis and size-exclusion membranes to isolate viable sperm without centrifugation, deli
Slide 4: Clinical evidence differentiates Felix and supports global adoption
CLINICAL VALIDATION Clinical evidence differentiates Felix and supports global adoption Felix 58.8% Density gradient centrifugation 49.1% Statistically superior to DGC for the primary outcome (Embryo Utilisation Rate) p=0.022 in a 103-couple, 10-centre Monash IVF study 100% of clinicians preferred C
Slide 5: Felix is building commercial access across major IVF markets
GLOBAL COMMERCIAL ACTIVATION Felix is building commercial access across major IVF markets Regulatory approvals and partner networks are now converting into clinic activation, orders and repeat cartridge demand EUROPE & UK AUSTRALIA Primary growth engine Monash IVF anchor CE Mark + MHRA access; Italy
Slide 6: Commercial milestones accelerated across FY2026
RAPID COMMERCIAL SCALE-UP Commercial milestones accelerated across FY2026 Approvals, anchor agreements and repeat orders have expanded commercial access across 31+ countries CE TGA 22 5 MARK APPROVAL CLINIC PATHWAY NORDIC MARKETS DEC 2025 FEB–MAY 2026 JUN–AUG 2026 SEP 2026 EUROPE OPENED ORDERS BUILD
Slide 7: Monash IVF provides a pathway from clinical validation to national adoption
AUSTRALIAN ANCHOR CUSTOMER Monash IVF provides a pathway from clinical validation to national adoption 12 months 2 sites 22 clinics 12,085 potential national deployment across stimulated IVF cycles reported by exclusive national supply agreement initial three-month rollout mainland capital cities Mo
Slide 8: MENA shows how distributor access can convert into recurring demand
COMMERCIAL MODEL IN ACTION MENA shows how distributor access can convert into recurring demand MARKET ACCESS PUBLIC TARGET ECONOMICS Five-year exclusive ITL agreement across MENA 15+ MENA countries Initial contracted minimum: 6,000 over five years; current annual minimum: 2,500 A$80–150 DEMAND SIGNA
Slide 9: Contracted demand is beginning to translate into orders and revenue
EARLY COMMERCIAL CONVERSION Contracted demand is beginning to translate into orders and revenue VIETNAM REVENUE BASE - $150,000 700 cartridges delivered or Registration achieved; 600-cartridge commercial order triggered. ordered THAILAND 200 + 6 cartridges + paid consoles Thai FDA approval activated
Slide 10: The next phase is demonstrating repeatable commercial adoption
INVESTMENT CASE The next phase is demonstrating repeatable commercial adoption De-risked platform Global commercial access Recurring revenue model Pivotal clinical evidence and approvals or Every Felix procedure uses a single-use Agreements across Australia, Europe, MENA, registrations across Europe
Slide 11: Capital structure provides context for valuation and potential dilution
CAPITAL STRUCTURE Capital structure provides context for valuation and potential dilution 3.087bn ~779.0M A$19M A$1.179M implied market capitalisation at ordinary shares on issue unlisted options on issue* cash at 30 June 2026 A$0.0065 close on 4 Sep 2026 CONVERTIBLE NOTE A$4.2 million · 8% coupon ·
Slide 12: Felix has reached its commercial inflection point
CLOSING THESIS Felix has reached its commercial inflection point Clinical validation, regulatory access and commercial agreements are now converting into clinic adoption, repeat cartridge demand and recognised revenue. VALIDATED CLEARED CONTRACTED CONVERTING SCALING → → → → Monash pivotal Key approv
Slide 13: Commercial footprint is active, converting and expanding
APPENDIX | COMMERCIAL FOOTPRINT Commercial footprint is active, converting and expanding Selected agreements are moving from market access into clinic activation, orders and repeat cartridge demand. ACTIVE & CONVERTING NEXT WAVE AUSTRALIA MENA TURKEY UK + JAPAN UK trials; & repeat use ,Japan repeat
Slide 14: Leadership supporting commercial execution
APPENDIX Leadership supporting commercial execution BOARD MANAGEMENT David Tasker Marjan Mikel Mathew Watkins Prof. John Aitken A/Prof. Hassan Bakos Non-Executive Director Director – Clinical Chairman Non-Executive Director Scientific Director Chair, Commercialisation Engagement & Growth 20+ years i
Slide 15: Disclaimer
IMPORTANT INFORMATION Disclaimer This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not
Slide 16: Investor & media enquiries
CONTACT Investor & media enquiries INVESTOR & MEDIA RELATIONS Colin Jacoby Chapter One Advisors cjacoby@chapteroneadvisors.com.au +61 439 980 359 ASX: MEM Commercialising Felix globally COMPANY memphasys.com Memphasys Limited ASX: MEM www.memphasys.com MEMPHASYS · ASX: MEM 19